In VivoThe reason Erik Wiklund can so clearly recall the evolution of the science of circular RNA is that he was there from the outset. “In the late 2000s, during my PhD work in molecular biology, Thomas Han
ScripVenture capital fundraising by biopharmaceutical companies has been a mixed bag so far in 2023, with a slow start to the year but a relative surge in big financings in March and April. There were only